A high powered delegation from a Cuban based pharmaceutical manufacturing company LABIOFAM over the weekend met with President Koroma to finalize agreement for the supply of Malaria drugs for patients in the country.
The head of delegation and also Director General of LABIOFAM Dr. Jose Antonio Fraga Castro disclosed to Awoko in an interview that LABIOFAM has been working closely with the West Africa Health Organization of ECOWAS Countries to supply malaria drugs.
He said the drugs are biologically effective to control and prevent malaria lavae in the water adding that Cuba developed the technology 30 yrs ago with chemicals that are applicable in under developed countries around the World.
Dr. Jose Antonio Fraga Castro said LABIOFAM drugs have been used in Africa, Europe and Asia; the drugs have been proven as the most effective to eradicate malaria by reducing the high rate of deaths among children and pregnant women. “We want to eradicate malaria in Sierra Leone” he assured.
He said LABIOFAM malaria drugs can prevent malaria bites and that it has been very effective in reducing malaria related deaths among children and pregnant women around the world.
He said during the meeting with President Koroma a contract document was presented to the Government of Sierra Leone through the ministry of Health and Sanitation for signing which is expected to take place in May next month. Dr. Jose Antonio Fraga Castro also said that the drugs are ready for supply in Sierra Leone.
He noted that the President is committed and determined to get malaria drugs as soon as possible to compliment the government initiative for free health care delivery across the country.
LABIOFAM is the only laboratory authorized by the Cuban Government to carry out the development and research Project on the use of the blue scorpion venom as a possible ant carcinogenic agent. It is a drug company owned by the Cuban government which headquarters and main production factories are located in Havana.
LABIOFAM works together with other Cuban state institutions in a multidisciplinary way. The work groups are composed of professionals completely qualified to carry out the ESCOZUL research and ESCOZUL production.
LABIOFAM also offers limited amounts of ESCOZUL to patients, mainly because its research requires great quantities of the blue scorpion venom. Its objectives focus on developing a research which will guarantee the properties of ESCOZUL and in this way help to obtain a patent and eventually develop a trademark.
By Saidu Bah